No Data
Wan Bond: Report for the first quarter of 2025
Wan Bond: 2024 Annual Report
Wan Bond: 2024 Annual Report Summary
Wanbangde Pharmaceutical Holding Group (002082.SZ): The net income attributable to the parent company for 2024 is 55.441 million yuan, an increase of 12.66% year-on-year.
Gelonghui, April 28 – Wanbangde Pharmaceutical Holding Group (002082.SZ) released its annual report for 2024. In 2024, the company achieved revenue of 1.443 billion yuan, a year-on-year decrease of 6.39%, with a net income of 55.441 million yuan, a year-on-year increase of 12.66%. Among them, the pharmaceutical manufacturing sector achieved revenue of 0.983 billion yuan, a year-on-year decrease of 6.71%, and a net income of 0.114 billion yuan, a year-on-year decrease of 18.43%; the medical instruments sector achieved revenue of 0.465 billion yuan, a year-on-year decrease of 6.08%, and a net income of -33.2512 million yuan, compared to the previous year.
Wanbangde Pharmaceutical Holding Group (002082.SZ): The clinical trial application for the pharmaceutical WP107 (Oral Solution of Huperzine A) has been accepted by the National Medical Products Administration.
On April 28, Gelonghui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received the "Acceptance Notice" approved by the National Medical Products Administration on April 24, 2025, for the clinical trial application of WP107 (an oral solution of huperzine A) for the treatment of myasthenia gravis.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Wanbangde Pharmaceutical Holding Group (SZSE:002082) Stock Falls a Further 15% in Past Week
Wanbangde Pharmaceutical Holding Group Co., Ltd. (SZSE:002082) Not Doing Enough For Some Investors As Its Shares Slump 28%
